In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm

With the rapid spread of antimicrobial resistance in Gram-negative pathogens, biofilm-associated infections are increasingly harder to treat and combination therapy with colistin has become one of the most efficient therapeutic strategies. Our study aimed to evaluate the potential for the synergy of...

Full description

Saved in:
Bibliographic Details
Main Authors: Tan, Jun Hou, Vidaillac, Celine, Yam, Joey Kuok Hoong, Chua, Song Lin, Givskov, Michael, Yang, Liang
Other Authors: School of Biological Sciences
Format: Article
Language:English
Published: 2017
Subjects:
Online Access:https://hdl.handle.net/10356/83882
http://hdl.handle.net/10220/42878
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-83882
record_format dspace
spelling sg-ntu-dr.10356-838822020-09-21T11:35:33Z In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm Tan, Jun Hou Vidaillac, Celine Yam, Joey Kuok Hoong Chua, Song Lin Givskov, Michael Yang, Liang School of Biological Sciences Lee Kong Chian School of Medicine (LKCMedicine) Singapore Centre for Environmental Life Sciences Engineering LpxC inhibitor Pseudomonas aeruginosa With the rapid spread of antimicrobial resistance in Gram-negative pathogens, biofilm-associated infections are increasingly harder to treat and combination therapy with colistin has become one of the most efficient therapeutic strategies. Our study aimed to evaluate the potential for the synergy of colistin combined with CHIR-090, a potent LpxC inhibitor, against in vitro and in vivo Pseudomonas aeruginosa biofilms. Four P. aeruginosa isolates with various colistin susceptibilities were chosen for evaluation. The tested isolates of P. aeruginosa exhibited MIC values ranging from 1 to 64 and 0.0625 to 0.5 μg/ml for colistin and CHIR-090, respectively. Against 24-h static biofilms, minimum biofilm eradication concentration values ranged from 256 to 512 and 8 to >128 μg/ml for colistin and CHIR-090, respectively. Interestingly, subinhibitory concentrations of CHIR-090 contributed to the eradication of subpopulations of P. aeruginosa with the highest colistin MIC values. The combination of colistin and CHIR-090 at subinhibitory concentrations demonstrated synergistic activity both in vivo and in vitro and prevented the formation of colistin-tolerant subpopulations in in vitro biofilms. In summary, our study highlights the in vivo and in vitro synergistic activity of the colistin and CHIR-090 combination against both colistin-susceptible and -nonsusceptible P. aeruginosa biofilms. Further studies are warranted to investigate the clinical relevance of the combination of these two antimicrobials and outline the underlying mechanism for their synergistic action. NRF (Natl Research Foundation, S’pore) MOE (Min. of Education, S’pore) Published version 2017-07-17T04:52:43Z 2019-12-06T15:33:49Z 2017-07-17T04:52:43Z 2019-12-06T15:33:49Z 2017 Journal Article Tan, J. H., Vidaillac, C., Yam, J. K. H., Chua, S. L., Givskov, M., & Yang, L. (2017). In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm. Antimicrobial Agents and Chemotherapy, 61(7), e02223-16-. 0066-4804 https://hdl.handle.net/10356/83882 http://hdl.handle.net/10220/42878 10.1128/AAC.02223-16 en Antimicrobial Agents and Chemotherapy © 2017 American Society for Microbiology. This paper was published in Antimicrobial Agents and Chemotherapy and is made available as an electronic reprint (preprint) with permission of American Society for Microbiology. The published version is available at: [http://dx.doi.org/10.1128/AAC.02223-16]. One print or electronic copy may be made for personal use only. Systematic or multiple reproduction, distribution to multiple locations via electronic or other means, duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper is prohibited and is subject to penalties under law. 9 p. application/pdf
institution Nanyang Technological University
building NTU Library
country Singapore
collection DR-NTU
language English
topic LpxC inhibitor
Pseudomonas aeruginosa
spellingShingle LpxC inhibitor
Pseudomonas aeruginosa
Tan, Jun Hou
Vidaillac, Celine
Yam, Joey Kuok Hoong
Chua, Song Lin
Givskov, Michael
Yang, Liang
In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm
description With the rapid spread of antimicrobial resistance in Gram-negative pathogens, biofilm-associated infections are increasingly harder to treat and combination therapy with colistin has become one of the most efficient therapeutic strategies. Our study aimed to evaluate the potential for the synergy of colistin combined with CHIR-090, a potent LpxC inhibitor, against in vitro and in vivo Pseudomonas aeruginosa biofilms. Four P. aeruginosa isolates with various colistin susceptibilities were chosen for evaluation. The tested isolates of P. aeruginosa exhibited MIC values ranging from 1 to 64 and 0.0625 to 0.5 μg/ml for colistin and CHIR-090, respectively. Against 24-h static biofilms, minimum biofilm eradication concentration values ranged from 256 to 512 and 8 to >128 μg/ml for colistin and CHIR-090, respectively. Interestingly, subinhibitory concentrations of CHIR-090 contributed to the eradication of subpopulations of P. aeruginosa with the highest colistin MIC values. The combination of colistin and CHIR-090 at subinhibitory concentrations demonstrated synergistic activity both in vivo and in vitro and prevented the formation of colistin-tolerant subpopulations in in vitro biofilms. In summary, our study highlights the in vivo and in vitro synergistic activity of the colistin and CHIR-090 combination against both colistin-susceptible and -nonsusceptible P. aeruginosa biofilms. Further studies are warranted to investigate the clinical relevance of the combination of these two antimicrobials and outline the underlying mechanism for their synergistic action.
author2 School of Biological Sciences
author_facet School of Biological Sciences
Tan, Jun Hou
Vidaillac, Celine
Yam, Joey Kuok Hoong
Chua, Song Lin
Givskov, Michael
Yang, Liang
format Article
author Tan, Jun Hou
Vidaillac, Celine
Yam, Joey Kuok Hoong
Chua, Song Lin
Givskov, Michael
Yang, Liang
author_sort Tan, Jun Hou
title In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm
title_short In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm
title_full In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm
title_fullStr In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm
title_full_unstemmed In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm
title_sort in vitro and in vivo efficacy of an lpxc inhibitor, chir-090, alone or combined with colistin against pseudomonas aeruginosa biofilm
publishDate 2017
url https://hdl.handle.net/10356/83882
http://hdl.handle.net/10220/42878
_version_ 1681059122466783232